Abstract

BackgroundInsulin glargine (Lantus®) is a long-acting basal insulin analog that demonstrates effective day-long glycemic control and a lower incidence of hypoglycemia than NPH insulin. After subcutaneous injection insulin glargine is partly converted into the two main metabolites M1 ([GlyA21]insulin) and M2 ([GlyA21,des-ThrB30]insulin). The aim of this study was to characterize the glargine metabolites in vitro with regard to their insulin receptor (IR) and IGF-1 receptor (IGF1R) binding and signaling properties as well as their metabolic and mitogenic activities.MethodsThe affinity of human insulin, insulin glargine and its metabolites to the IR isoforms A and B or IGF1R was analyzed in a competitive binding assay using SPA technology. Receptor autophosphorylation activities were studied via In-Cell Western in CHO and MEF cells overexpressing human IR-A and IR-B or IGF1R, respectively. The metabolic response of the insulins was studied as stimulation of lipid synthesis using primary rat adipocytes. Thymidine incorporation in Saos-2 cells was used to characterize the mitogenic activity.ConclusionsThe binding of insulin glargine and its metabolites M1 and M2 to the IR were similar and correlated well with their corresponding autophosphorylation and metabolic activities in vitro. No differences were found towards the two IR isoforms A or B. Insulin glargine showed a higher affinity for IGF1R than insulin, resulting in a lower EC50 value for autophosphorylation of the receptor and a more potent stimulation of thymidine incorporation in Saos-2 cells. In contrast, the metabolites M1 and M2 were significantly less active in binding to and activation of the IGF1R and their mitogenicity in Saos-2 cells was equal to human insulin. These findings strongly support the idea that insulin glargine metabolites contribute with the same potency as insulin glargine to blood glucose control but lead to significantly reduced growth-promoting activity.

Highlights

  • Insulin glargine (LantusH, [GlyA21,ArgB31,ArgB32]insulin) is a longacting human insulin analog with an almost peakless activity profile very closely mimicking the natural physiological profile of basal endogenous insulin secretion [1,1,2,3,4,5]

  • Insulin glargine differs from human insulin by substitution of asparagine by glycine in position 21 of the A chain and by carboxy-terminal extension of the B-chain by two arginine residues

  • In the present study we provide insulin receptor (IR)- and IGF-1 receptor (IGF1R)-mediated metabolic and mitogenic signaling profiles for insulin glargine, IM, M1, and M2, including the differentiation between IR-A and IR-B

Read more

Summary

Introduction

Insulin glargine (LantusH, [GlyA21,ArgB31,ArgB32]insulin) is a longacting human insulin analog with an almost peakless activity profile very closely mimicking the natural physiological profile of basal endogenous insulin secretion [1,1,2,3,4,5]. Insulin glargine differs from human insulin by substitution of asparagine by glycine in position 21 of the A chain and by carboxy-terminal extension of the B-chain by two arginine residues. These alterations cause a shift in the isoelectric point from pH 5.4 to 6.7. The aim of this study was to characterize the glargine metabolites in vitro with regard to their insulin receptor (IR) and IGF-1 receptor (IGF1R) binding and signaling properties as well as their metabolic and mitogenic activities

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call